CAR T (Tsarin Mai karɓar Antigen na Chimeric)
Shirye-shiryen maganin salon salula na Sorrento sun mayar da hankali kan Chimeric Antigen Receptor-T Cell (CAR T) don maganin rigakafi na salula don magance ciwace-ciwacen ƙwayoyi da ruwa.
Shirin CAR T ya ƙunshi CD38, CEA da CD123.
CD38 CAR T na Sorrento yana yin hari ga manyan ƙwayoyin CD38 masu inganci, wanda zai iya iyakance gubar kan-manufa/ kashe-kashe.
A halin yanzu ana kimanta ɗan takarar CD38 CAR T na kamfanin a cikin myeloma da yawa (MM). Shirin ya sami nasarar nuna aikin rigakafin ƙwayar cuta mai ƙarfi a cikin samfuran dabbobi kuma a halin yanzu yana cikin gwaji na 1 a cikin RRMM. Bugu da ƙari, Sorrento ya ba da rahoton bayanai daga gwaji na Mataki na I na carcinoembryonic antigen (CEA) da ke jagorantar shirin CAR T.
Kamfanin yana tantance CD123 CAR T a cikin m myeloid cutar sankarar bargo (AML).
DAR T (Dimeric Antigen Receptor-T Cell)
Sorrento yana amfani da fasaha na ƙwanƙwasa (KOKI) na mallakar mallaka don gyara masu ba da lafiya na yau da kullun waɗanda aka samo T sel don injiniyoyin su don bayyana dimeric antigen receptor zuwa T-cell receptor (TCR) alpha chain constant area (TRAC). Ta wannan hanyar, ana fitar da TRAC kuma an buga antigen a cikin wurinsa.
Dimeric Antigen Receptor (DAR) yana amfani da Fab a maimakon scFv da ƙwayoyin T sel na Chimeric Antigen Receptor (CAR) na gargajiya ke amfani dashi. Mun yi imanin an nuna wannan DAR a cikin takamaiman binciken bincike mafi girma, kwanciyar hankali da ƙarfi.
Chimeric Antigen Receptors (CARs)

Fasahar Salon CAR T na yanzu
Fasaha na gaba-Gen Dimeric Antigen Receptor (DAR).
